Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03431714
Other study ID # NIMR-Tanzania
Secondary ID
Status Completed
Phase Phase 4
First received December 22, 2017
Last updated February 12, 2018
Start date July 14, 2017
Est. completion date December 8, 2017

Study information

Verified date February 2018
Source National Institute for Medical Research, Tanzania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The World Health Organization recommends regular surveillance of antimalarial efficacy to monitor the performance of different drugs. The Tanzanian National Malaria Control Programme (NMCP) in collaboration with its partners have been implementing therapeutic efficacy studies (TES) to monitor the performance of different antimalarials in the country. Most of the studies conducted in recent years focused on artemether-lumefantrine which is the first line antimalarial for the treatment of uncomplicated malaria in Mainland Tanzania. However, data on the performance of other artemisinin based combination therapy (ACTs) is urgently needed to support timely review and changes of treatment guidelines in case of drug resistance to current regimen. This study was undertaken in the same NMCP framework to assess the efficacy and safety of alternative ACTs used or with potential use in Tanzania. The study assessed the efficacy and safety of artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated malaria in Tanzania. The study was undertaken at two NMCP sentinel sites of Kibaha and Ujiji from July to December 2017.


Recruitment information / eligibility

Status Completed
Enrollment 333
Est. completion date December 8, 2017
Est. primary completion date December 8, 2017
Accepts healthy volunteers No
Gender All
Age group 6 Months to 10 Years
Eligibility Inclusion Criteria:

- Patients aged 6 months to 10 years.

- mono-infection with P. falciparum detected by microscopy;

- parasitaemia of 250 - 200,000/µl asexual forms;

- presence of axillary temperature =37.5 °C or history of fever during the past 24 hours

- ability to swallow oral medication;

- ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and

- Informed consent from the parents or guardians of children.

Exclusion Criteria:

- mRDT negative

- presence of general danger signs in children aged 6 months to 10 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);

- weight under 5 Kg

- mixed or mono-infection with another Plasmodium species detected by microscopy;

- presence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet or has a mid-upper arm circumference < 110 mm in children = 59 months; or BMI of <16 in children aged 5 years and above)

- presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);

- regular medication, which may interfere with antimalarial pharmacokinetics;

- history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);

Study Design


Intervention

Drug:
Artesunate amodiaquine
Drugs were administered under observation of the study nurse for three days

Locations

Country Name City State
Tanzania National Institute for Medical Research Tanga

Sponsors (3)

Lead Sponsor Collaborator
National Institute for Medical Research, Tanzania Muhimbili University of Health and Allied Sciences, World Health Organization

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adequate clinical response Proportions of patients with 100% cure before PCR correction 28 days
Secondary PCR corrected responses Proportions of patients with 100% cure after PCR correction one months after study completion
See also
  Status Clinical Trial Phase
Withdrawn NCT00936767 - Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia Phase 2/Phase 3
Withdrawn NCT02461186 - Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar Phase 2/Phase 3
Active, not recruiting NCT04009343 - Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials Phase 2/Phase 3
Completed NCT00682578 - A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan Phase 3
Completed NCT00959517 - Trial of Artesunate Combination Therapy in Pakistan Phase 2
Recruiting NCT00902811 - Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Phase 4
Completed NCT01407887 - Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children Phase 2
Completed NCT00356005 - Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh Phase 2